A mbulatory blood pressure (BP), typically measured over a 24-hour period, is a strong and independent predictor of hypertension-related adverse cardiovascular and renal outcomes. [1] [2] [3] [4] [5] A key feature of ambulatory BP compared with traditional clinic-based measurement is the ability to assess BP throughout the day and night in the setting of usual Abstract-The effect of clinic-based intensive hypertension treatment on ambulatory blood pressure (BP) is unknown.
activities, rather than at a single time point in the clinician's office. Observational studies consistently demonstrate that nighttime BP is a better predictor of clinical outcomes than daytime and clinic-based BP. [2] [3] [4] 6 All large randomized trials in hypertension have used clinic-based BP to determine eligibility and to target antihypertensive drug therapy. The impact of clinic-based hypertension treatment on ambulatory BP is less well studied; a meta-analysis of clinical trials that evaluated ambulatory BP at baseline and after an intervention found that for every 10 mm Hg decrease in clinic systolic BP, ambulatory systolic BP decreases by 4.2 mm Hg. 7 Even less is known about the effect of targeting different levels of clinic BP on measures of ambulatory BP. In the HOT trial (Hypertension Optimal Treatment), which targeted 3 different levels of clinic diastolic BP, there was no difference in 24-hour ambulatory BP between treatment arms. 8 This may relate to the small differences in achieved clinic diastolic BP between the 3 arms in this study. Data on the impact of targeting different levels of clinic systolic BP on ambulatory BP are limited. If lower treatment goals are more broadly incorporated into clinical practice, it will be important to understand the effect of intensive clinic-based BP lowering strategies on ambulatory BP.
The SPRINT (Systolic Blood Pressure Intervention Trial) was a large multicenter, randomized, controlled trial in 9361 people with a systolic BP of 130 mm Hg or higher and an increased cardiovascular risk, but without diabetes mellitus or prevalent stroke. SPRINT demonstrated significant reductions in cardiovascular events (25%) and mortality (27%) with treatment of clinic systolic BP to a target of <120 mm Hg (intensive treatment) compared with a target of <140 mm Hg (standard treatment). We measured ambulatory BP in a subset of participants in the SPRINT study at selected clinical sites. The goal of this analysis was to evaluate the difference in nighttime systolic BP, as well as other ambulatory BP-derived parameters (daytime systolic BP, 24-hour systolic BP, night/day systolic BP ratio, and 24-hour BP variability) between the intensive and standard clinic-based BP treatment groups in SPRINT.
Methods
The design and main results of SPRINT have been published. 9, 10 SPRINT was a 2-arm, multicenter, randomized trial. Participants met all the following criteria: an age of at least 50 years, a clinic systolic BP of 130 to 180 mm Hg (with the acceptable upper limit for clinic systolic BP decreasing as the number of pretrial antihypertensive medications increased), and an increased risk of cardiovascular events defined by one or more of the following: clinical or subclinical cardiovascular disease (CVD) other than stroke; chronic kidney disease; a 10-year risk of CVD of 15% or greater on the basis of the Framingham risk score; or an age of 75 years or older. Patients with diabetes mellitus, previous stroke, symptomatic heart failure within the past 6 months, or left ventricular ejection fraction <35% were excluded. Eligible participants were randomly assigned to a clinic systolic BP target of <120 mm Hg (the intensive-treatment group) or <140 mm Hg (the standardtreatment group). During a median 3.26 years of follow-up, the mean clinic systolic BP was 121.5 mm Hg in the intensive-treatment group and 134.6 mm Hg in the standard-treatment group. 9 Consecutive SPRINT participants at 15 clinical sites were approached to participate in the ambulatory BP ancillary study at the 27-month follow-up visit. The protocol was approved by the Institutional Review Board at each of the participating sites. Eligible SPRINT participants willing to participate in this ancillary study provided informed consent for ambulatory BP monitoring (ABPM).
Exclusion criteria were as follows: (1) arm circumference >50 cm, (2) shift worker or work regularly at night, (3) history of breast cancer requiring mastectomy or radiation on the nondominant arm (to avoid frequent BP measurements in patients with lymphedema), and (4) end-stage renal disease.
Clinic BP was obtained using an automated measurement device (HEM-907 XL, Omron Healthcare, Lake Forest, IL). Clinic staff was instructed to set the monitor to automatically wait 5 minutes and then obtain 3 measurements at 1 minute intervals. The mean of the 3 BP measurements was used for these analyses. Clinical and laboratory data were obtained at the 24-and 27-month study visits.
Ambulatory BP was measured within 3 weeks of the 27-month study visit using SpaceLabs Medical Model 90207 monitors using a 24-hour protocol based on the recommendations from the British Hypertension Society and previous studies, which used similar criteria. [11] [12] [13] [14] Briefly, the monitor was placed on the participant's nondominant arm, recorded BP every 30 minutes, and was set so that the readings were not displayed. Written instructions about the procedure were provided to participants, and they were asked to keep a record of antihypertensive medication dosing. A recording was deemed to be acceptable if there were at least 14 readings between 6:00 am and 12:00 midnight and at least 6 readings between 12:00 midnight and 6:00 am. 13, 14 Clinical site staff were trained to follow a standard manual of procedures for obtaining clinic and ambulatory BP.
As recommended by the European Society of Hypertension, nighttime systolic BP was defined as the average of all systolic BP readings during the 1 am to 6 am window; daytime systolic BP was defined as the average of all systolic BP readings during the 9 am to 9 pm window. 15 The 6 am to 9 am and 9 pm to 1 am windows are not included to avoid the transition periods between wake and sleep time, although in other studies in the field only 2 hours were excluded for analyses. 16 Participants were categorized by the night/day ambulatory systolic BP ratio: extreme dippers (<0.8), dippers (≥0.8 and ≤0.9), nondippers (>0.9 and ≤1), and reverse dippers (>1). BP variability was defined for each participant by the weighted average of the daytime and nighttime SD. 17 Secondary analyses defined BP variability by calculating average real variability.
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Statistical Analyses
The difference in nighttime systolic BP between treatment groups was evaluated using linear regression with adjustment for clinical site. In secondary analyses, we adjusted for age, sex, race, estimated glomerular filtration rate, smoking (current, former, or never smoker), alcohol use (unknown, nondrinker: <1 drink per month, light drinker: 1 drink per month to <3 drinks per week, moderate drinker: ≥3 drinks per week but <2 drinks per day, or heavy drinker: ≥2 drinks per day), evening dosing of hypertension medications (nighttime and 24-hour ABPM measures), and morning dosing of hypertension medications (daytime and 24-hour ABPM measures) as covariates. We tested for interaction between treatment group and the prespecified subgroups for SPRINT: previous chronic kidney disease (estimated glomerular filtration rate based on the MDRD study equation <60 mL min −1 per 1.73 m 2 ), sex, race (black versus nonblack), previous CVD, and baseline systolic BP tertiles (<133, 133 to <145, or ≥145 mm Hg). Similar analyses were conducted for the secondary outcomes of 24-hour systolic BP, daytime systolic BP, night/day systolic BP ratio, and BP variability. The BP variability metrics (SD and average real variability) were both log-transformed before regression modeling; therefore, effect estimates represent multiplicative effects on the mean for these measures. We examined the concordance between clinic and ambulatory BP measures by calculating Spearman correlations and graphically using Bland-Altman plots. 19 On the basis of previous ABPM studies, we assumed a SD for nighttime systolic BP between 12 and 16 mm Hg. 1, 2 Assuming an α level of 0.05, we estimated that 400 participants per group would provide 80% power to detect a 3 mm Hg difference in nighttime systolic BP between treatment groups.
Results
Acceptable ambulatory BP recordings were obtained in 897 SPRINT participants (Figure 1 ). The median number of days between the 27-month study visit and ambulatory BP measurement was 0 (interquartile range 0-6 days). Characteristics of participants who underwent ABPM by treatment group are shown in Table 1 . At the time of ABPM, mean age of the participants was 71.5 years, 29% were female, and 28% were black. There were no significant differences in baseline demographic characteristics, Framingham risk, or history of CVD between treatment groups. The estimated glomerular filtration rate (mean 67.3 versus 73.4 mL min −1 per 1.73 m 2 ; P<0.001) and urine albumin:creatinine ratio were lower (median 7.9 versus 10.6 mg/g; P<0.001) in the intensivetreatment group compared with the standard-treatment group at the 24-month study visit. As expected, participants in the intensive-treatment group were on more antihypertensive medications at the 27-month study visit. A greater percentage of participants in the intensive-treatment group took an antihypertensive medication at night (6 pm to 2 am; 39% versus 31% in the standard-treatment group; P=0.026); a similar difference was noted for morning dosing (4 am to 10 am; 77% versus 62% in the standard-treatment group; P<0.001).
In this study population, clinic systolic BP at the 27-month follow-up visit was 119.7±12.8 mm Hg in the intensive-treatment group and 135.5±13.8 mm Hg in the standard-treatment group (Table 2) . Nighttime systolic BP was lower in the intensive-treatment group compared with the standard-treatment group (115.7±14.6 versus 125.5±14.6 mm Hg), as were daytime systolic BP (126.5±12.3 versus 138.8±12.6 mm Hg) and 24-hour systolic BP (122.7±12.0 versus 134.0±11.8 mm Hg). The adjusted difference in systolic BP between the intensive-treatment and standardtreatment groups was greater when measured in clinic (16.4 mm Hg) versus nighttime BP (9.8 mm Hg), daytime BP (12.1 mm Hg), or 24-hour BP (11.2 mm Hg; Table 3 ). There were no differences between treatment groups with regard to dipping status or night/day systolic BP ratio (Tables 2 and 3 ). Values are n (%), mean±SD, or median (25th percentile to 75th percentile). Baseline denotes data collected at randomization visit; 24 mo, data collected at 24-mo annual visit; and 27 mo, data collected at 27-mo study visit. ABPM indicates ambulatory blood pressure monitoring; ACE, angiotensin-converting enzyme; CVD, cardiovascular disease; eGFR, estimated glomerular filtration rate based on the Modification of Diet in Renal Disease study equation; HDL, high-density lipoprotein; and LDL, low-density lipoprotein.
BP variability was lower in the intensive-treatment group when assessed by both weighted day/night SD and absolute real variability (Table 3) .
The difference in nighttime systolic BP between the intensive-treatment and standard-treatment groups was smaller in participants with chronic kidney disease at the SPRINT Nighttime defined based on narrow clock time (1:00 am to 6:00 am). Daytime was also based on narrow clock time (9:00 am and 9:00 pm). ARV indicates average real variability, BP, blood pressure; and CI, confidence interval.
*Numbers for SD and ARV are median (interquartile range). Differences for these variables were modeled on a log-scale; therefore, estimates represent multiplicative effects on the mean. Estimates denote mean effect for standard-treatment group based on general linear model. Variability metrics (SD and ARV) were modeled on log-scale, therefore, estimates represent multiplicative effects on the mean. Primary analyses only adjust for clinic site. Secondary analyses also adjust for age, sex, race/ethnicity, estimated glomerular filtration rate, smoking status, and alcohol use. Nighttime systolic blood pressure (BP) also adjusted for nighttime dosing of antihypertensive medications (between 6 pm and 2 am), whereas daytime systolic BP was also adjusted for dosing of antihypertensive medications between 4 am and 10 am. All other ambulatory BP monitoring measures were adjusted for antihypertensive medication use between 6 pm and 2 am and between 4 am and 10 am. ARV indicates average real variability; and CI, confidence interval. baseline visit and also smaller for participants 75 years of age or older, although the interaction between age and treatment group was not statistically significant ( Figure 2) . The difference in nighttime BP between treatment groups was consistent for subgroups defined by sex, race, previous CVD, and baseline systolic BP. Similar results by subgroups were observed for daytime and 24-hour ambulatory BP, except that the difference between treatment groups was also smaller among females and participants 75 years or older (Figures S1 and S2 in the online-only Data Supplement).
There was a moderate agreement between clinic systolic BP at the 27-month visit and daytime ambulatory systolic BP (Spearman correlation=0.56, P<0.001). However, Bland-Altman plots indicated poor agreement with limits of agreement ranging from −19.3 to 32.7 mm Hg for the intensive-treatment group and −24.8 to 32.3 mm Hg for the standard-treatment group ( Figure 3A) . Similar levels of agreement were observed between clinic systolic BP at the 24-month and 27-month study visits, with limits of agreement of −27.9 to 32.1 mm Hg for the intensive-treatment group and −31.2 to 35.2 mm Hg for the standard-treatment group ( Figure 3B) .
Discussion
Our results demonstrate that intensive clinic-based hypertension treatment lowers nighttime systolic BP, daytime systolic BP, and 24-hour systolic BP compared with standard clinicbased hypertension treatment. The difference in ambulatory BP between groups was less than the difference measured by clinic BP. In addition, there was no difference in diurnal change in BP between groups.
The SPRINT ambulatory BP ancillary study results are consistent with previous reports, indicating that interventions targeting clinic BP reduce clinic BP more than 24-hour ambulatory BP and daytime ambulatory BP more than nighttime ambulatory BP. In the Symplicity HTN-2 Trial, renal sympathetic denervation resulted in a 32 mm Hg decrease in clinic systolic BP at 6 months, but only an 11 mm Hg decrease in 24-hour ambulatory systolic BP. 20 In the 3A observational study, clinic systolic BP decreased by 19 mm Hg 1 year after antihypertensive intensification, whereas 24-hour ambulatory systolic BP decreased by only 10 mm Hg. All previous results are based on baseline (pretreatment) and follow-up (posttreatment) clinic and ambulatory BP measurements in observational studies and nontreat to target randomized trials. The HOT trial did measure ambulatory BP in a substudy; however, it showed no difference in 24-hour ambulatory diastolic or systolic BP between randomized diastolic BP groups. The sample size for the HOT ambulatory BP substudy was relatively small, and there were only small differences in clinic BP between treatment arms. 8 The SPRINT ambulatory BP results, therefore, represent the best demonstration of the impact of intensive clinic BP lowering therapy on ambulatory BP.
There are several important implications of our results. This study confirms that there was a significant BP difference between the intensive-treatment and standard-treatment groups using an independent technique of measuring BP. Our results show that SPRINT achieved a significant difference in nighttime and daytime systolic BP. Results were consistent across most subgroups, although the difference in ambulatory BP between treatment groups was lower among participants with chronic kidney disease, those 75 years of age or older, and females. ABPM may be of more benefit in patients with these characteristics given the smaller impact of intensive treatment on ambulatory BP, which may increase the likelihood of discordance between clinic and ambulatory BPs. It is interesting to note that daytime ambulatory systolic BP was 6.85 mm Hg higher than clinic systolic BP in the intensive-treatment group, compared with 3.30 mm Hg higher in the standard-treatment group. This finding suggests that ABPM may be more important when implementing intensive clinic-based hypertension therapy to assess for higher BP outside the office compared with the clinical setting. This profile of BP, commonly referred to as masked hypertension, is associated with increased risk for hypertension-related adverse outcomes. [1] [2] [3] [4] [5] In SPRINT, intensive lowering of clinic BP resulted in significant reductions in ambulatory BP, cardiovascular events, and all-cause mortality. 9 Therefore, at least indirectly, SPRINT suggests that reductions in ambulatory BP are associated with improved clinical outcomes. The reduction in cardiovascular events and all-cause mortality may be due in part to the reduction in nighttime BP and BP variability observed with intensive lowering of clinic BP in this study. The decrease in BP variability may be because of the lower clinic BP target or the increased use of antihypertensive medications associated with lower BP variability such as chlorthalidone and calcium channel blockers. 21 The effect of the intensive clinic BP target on ambulatory BP may also be due in part to increased utilization of these long-acting medications. Surprisingly, there was no difference in the diurnal change in BP between treatment groups. Recent studies indicate that nighttime hypertension itself, rather than diurnal change in BP, is associated with adverse outcomes. 22, 23 The United States Preventive Services Task Force recently made a grade A recommendation for the measurement of ambulatory BP in patients with elevated clinic BP to confirm the diagnosis of hypertension before initiating treatment. 24, 25 This recommendation is based on observational studies demonstrating that ≈25% of patients with elevated clinic BP have normal BP outside the clinic, known as whitecoat hypertension; patients with white-coat hypertension are at low risk for adverse outcomes. 26 As mentioned previously, it remains unknown whether patients with white-coat hypertension benefit from antihypertensive therapy because nearly all hypertension trials have not included measurement of ambulatory BP at baseline.
Of note, clinic BP was lower than daytime ambulatory BP in SPRINT. This could be because of the careful guideline-based measurement of clinic BP in SPRINT, use of an automated device, and a lower white-coat effect because participants were coming to a known environment and staff and were allowed to rest alone for 5 minutes before BP measurement. 27 Our results reinforce the concept that ambulatory BP is required to assess the burden of hypertension during the course of patients' usual activities in their environment and cannot be reliably estimated by clinic BP readings. Finally, although we measured BP outside the research setting with ABPM, the BP achieved in the routine clinic setting remains unknown. Given that BP is not measured per American Heart Association recommendations in most clinics, understanding the achieved BP in the routine clinic setting during the treat to target phase is critically important to implementing SPRINT results.
Our study has important limitations. Ambulatory BP was not measured at the baseline visit in SPRINT. This limits our ability to assess how intensive and standard treatment strategies affect ambulatory and nighttime BP within individuals and to identify patient characteristics associated with ambulatory BP responses to treatment. Ambulatory BP was assessed in only a subset of SPRINT participants; however, the subjects who did and did not participant in the SPRINT ABPM ancillary study had similar baseline characteristics (Table S1) , and only 5% were excluded because of compliance concerns. While there is robust epidemiological literature documenting the predictive value of nighttime BP, whether lowering nighttime BP improves outcomes is not resolved. 6, 13 SPRINT was not designed to lower nighttime BP specifically, and, therefore, our findings are post hoc and do not fully resolve this issue. Finally, ambulatory BP was only assessed at 1 visit, and BP categorization, such as white-coat hypertension, may vary over time in ≤25% of patients. 28 Although the importance of ABPM is increasingly being recognized, several issues that are important to fully leverage ABPM to improve hypertensive patients' outcomes remain unresolved. It is unknown whether treating patients with normal clinic BP and elevated ambulatory BP, known as masked hypertension, reduces risk for CVD and renal disease; similarly, it is unknown whether withholding therapy for patients with elevated clinic BP and normal ambulatory BP (white-coat hypertension) is safe. In addition, in patients with elevated clinic and ambulatory BP, it is unknown whether a treatment strategy targeting ambulatory BP reduces adverse outcomes compared with a conventional strategy targeting clinic BP. Another important issue that our data cannot address relates to evening dosing of antihypertensive medications, which has been shown to reduce nighttime BP and risk for CVD. 29, 30 Although nighttime BP was lower in the intensive-treatment group and a greater percent of intensive-treatment versus standard-treatment participants took an antihypertensive medication in the evening (39% versus 31%), the effect of evening dosing with either intensive or standard clinic-based BP targets was not assessed. Further studies are needed to assess whether targeting hypertension therapy based on ambulatory BP reduces adverse outcomes compared with clinic-based therapy, and whether evening dosing of antihypertensive therapy reduces risk for CVD.
Perspectives
This is the first study to demonstrate the effect of intensive and standard clinic-based systolic BP targets on ambulatory BP. Compared with standard treatment, intensive treatment of clinic BP resulted in lower nighttime, daytime, and 24-hour ambulatory BP, as well as BP variability but did not alter the diurnal BP pattern. However, there was a greater difference in clinic BP than ambulatory BP; in addition, the within participant agreement between clinic and ambulatory BP was low. These results highlight the importance of ambulatory BP to assess the true burden of hypertension during treatment. Final, given the increasing awareness of ambulatory BP for defining hypertension-related risk for adverse outcomes, the SPRINT ambulatory BP results will inform the design of hypertension trials that move beyond clinic BP to evaluate the potential benefits of new treatment strategies.
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What Is New?
• This is the first study to demonstrate the effect of intensive and standard clinic-based systolic blood pressure (BP) targets on ambulatory BP.
What Is Relevant?
• These results highlight the importance of ambulatory BP to assess the true burden of hypertension during treatment.
• Given the increasing awareness of ambulatory BP for defining hypertension-related risk for adverse outcomes, the SPRINT (Systolic Blood Pressure Intervention Trial) ambulatory BP results will inform the design of hypertension trials that move beyond clinic BP to evaluate the potential benefits of new treatment strategies.
Summary
Targeting a systolic BP of <120 mm Hg, when compared with <140 mm Hg, resulted in lower nighttime, daytime, and 24-hour systolic BP, but did not change the night/day systolic BP ratio. Further studies are needed to assess whether targeting hypertension therapy based on ambulatory BP improves clinical outcomes.
Novelty and Significance
